Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Payables (2024 - 2025)

Drugs Made In America Acquisition filings provide 2 years of Payables readings, the most recent being $222184.0 for Q4 2025.

  • Quarterly Payables fell 69.96% to $222184.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $222184.0 through Dec 2025, down 69.96% year-over-year, with the annual reading at $222184.0 for FY2025, 69.96% down from the prior year.
  • Payables hit $222184.0 in Q4 2025 for Drugs Made In America Acquisition, up from $1000.0 in the prior quarter.
  • Across five years, Payables topped out at $739604.0 in Q4 2024 and bottomed at $1000.0 in Q2 2025.